FDA Updates Contraindications for Myrbetriq
The U.S. Food and Drug Administration (FDA) has updated the label on Myrebetriq to include a new contraindication and additional information in the Warnings and Precautions section. The revised label now states that the drug, which is used to treat an overactive bladder, is contraindicated in patients who are hypersensitive to … [Read more...]
Macugen Labeling Change
Macugen Labeling Change. Pfizer Pharmaceuticals notified healthcare professionals of important changes in the approved product labeling for Macugen (pegaptanib sodium injection), including changes to the CONTRAINDICATIONS, PRECAUTIONS, ADVERSE EVENTS Post-Marketing, and DOSAGE and ADMINISTRATION sections. Rare reports of … [Read more...]

Leave a Reply
You must be logged in to post a comment.